1. Ren Y, Zheng J, Fan S et al. Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification. Oncotarget 2017; 8: 50832-50844.
2. Zhang L, Yang J, Cai J et al. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep 2013; 3: 2992.
3. El Guerrab A, Bamdad M, Kwiatkowski F et al. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget 2016; 7:
73618-73637.
4. Fukuoka S, Kojima T, Koga Y et al. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. Oncotarget 2017; 8: 11020-11029.
5. Wang X, Fu R, Hu Y et al. EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patientderived xenografts with cetuximab. Oncol Rep 2017; 38:
2387-2393.
6. Black PC, Brown GA, Inamoto T et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008; 14: 1478-1486.
7. Kato S, Okamura R, Mareboina M et al. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol 2019; 3.
8. Wang Y, Jiang CQ, Guan J et al. Molecular alterations of EGFR in small intestinal
adenocarcinoma. Int J Colorectal Dis 2013; 28: 1329-1335.
9. Smyth EC, Vlachogiannis G, Hedayat S et al. EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. Gut 2020.
10. Birkman EM, Algars A, Lintunen M et al. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus. BMC Cancer 2016; 16: 406.
11. Higaki E, Kuwata T, Nagatsuma AK et al. Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method. Gastric Cancer 2016; 19: 63-73.
12. Dahle-Smith A, Stevenson D, Massie D et al. Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma. Mol Cytogenet 2015; 8: 78.
13. Lin G, Sun XJ, Han QB et al. Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma. Oncol Lett 2015; 10: 901-906.
14. Guo K, Wang WP, Jiang T et al. Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer. J Thorac Dis 2016; 8: 1753-1763.
15. Jiang D, Li X, Wang H et al. The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma. BMC Cancer 2015; 15: 377.
16. Park HS, Jang MH, Kim EJ et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol 2014; 27: 1212-1222.
17. Silva Amancio AM, Cunha IW, Neves JI et al. Epidermal growth factor receptor as an adverse survival predictor in squamous cell carcinoma of the penis. Hum Pathol 2017; 61: 97-104.
18. Iida K, Nakayama K, Rahman MT et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. Br J Cancer 2011; 105: 420-427.
19. Chang H, Yang Y, Lee JS et al. Epidermal Growth Factor Receptor Gene Amplification Predicts Worse Outcome in Patients With Surgically Resected Nonadenocarcinoma Lung Cancer. Clin Lung Cancer 2019; 20: 7-12.e11.
20. Rakosy Z, Vizkeleti L, Ecsedi S et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 2007; 121: 1729-1737.
21. Ajani JA, Ryan B, Rich TA et al. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer 1992; 28a: 880-884.
22. Iizuka T, Kakegawa T, Ide H et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992; 22: 172-176.
23. Kato K, Cho BC, Takahashi M et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology 2019; 20:
1506-1517.
24. Kojima T, Shah MA, Muro K et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol 2020; 38:
4138-4148.
25. Dutton SJ, Ferry DR, Blazeby JM et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. The Lancet Oncology 2014; 15: 894-904.
26. Petty RD, Dahle-Smith A, Stevenson DAJ et al. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. J Clin Oncol 2017; 35: 2279-2287.
27. Huang J, Fan Q, Lu P et al. Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study. J Thorac Oncol 2016; 11: 910-917.
28. Maron SB, Alpert L, Kwak HA et al. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov 2018; 8: 696-713.
29. Nakamura Y, Sasaki A, Yukami H et al. Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab. JCO Precis Oncol 2020.
30. Byeon S, Hong JY, Lee J et al. Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. Target Oncol 2020; 15: 185-192.
31. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
Lancet Oncol 2005; 6: 279-286.
32. Herbst RS, Redman MW, Kim ES et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet Oncology 2018; 19: 101-114.
33. Genova C, Socinski MA, Hozak RR et al. EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol 2018; 13: 228-236.
34. Shitara K, Doi T, Dvorkin M et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19: 1437-1448.
35. Kang YK, Boku N, Satoh T et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet 2017; 390: 2461-2471.
36. Zaanan A, Gauthier M, Malka D et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer 2011; 117: 1422-1428.
37. Overman MJ, Adam L, Raghav K et al. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 2018; 29: 139-144.